- Home
- APLT vs PGRE Comparison
APLT vs PGRE Comparison
Compare APLT & PGRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APLT | PGRE |
|---|---|---|
| Founded | 2016 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.1M | 1.5B |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | APLT | PGRE |
|---|---|---|
| Price | $0.13 | $6.60 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 5 |
| Target Price | $1.25 | ★ $6.80 |
| AVG Volume (30 Days) | ★ 8.7M | 2.5M |
| Earning Date | 11-13-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,000,000.00 | ★ $681,644,000.00 |
| Revenue This Year | $124.18 | $1.86 |
| Revenue Next Year | $66.67 | $1.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 23.12 |
| 52 Week Low | $0.10 | $3.75 |
| 52 Week High | $1.50 | $7.85 |
Technical Indicators
Market Signals| Indicator | APLT | PGRE |
|---|---|---|
| Relative Strength Index (RSI) | 27.06 | 56.95 |
| Support Level | $0.10 | $6.56 |
| Resistance Level | $0.13 | $6.64 |
| Average True Range (ATR) | 0.02 | 0.02 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 17.28 | 50.00 |
Price Performance
Historical ComparisonAbout APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About PGRE Paramount Group Inc.
Paramount Group Inc is a real estate investment trust engaged in owning, operating, managing, acquiring, and redeveloping high-quality, Class A office properties in select central business district (CBD) submarkets of New York City and San Francisco. The company operates in two geographical segments New York and San Francisco. The company derives nearly all of its majority of revenue from rental income.